Sistema nervoso central no LES | Reumatize Podcast | Episódio 27

Key Points

• Neuropsychiatric lupus (NPSLE) encompasses a wide range of syndromes, from mild symptoms like headache to severe ones like stroke, acute confusional state, and psychosis, with a prevalence estimated between 30-50%.
• Diagnosing NPSLE is challenging as neurological symptoms in lupus patients can be due to the disease itself, medication side effects, infections, metabolic issues, or other conditions; only about one-third of cases are directly lupus-related.
• Severe central nervous system manifestations include acute confusional state/delirium, cognitive decline, and stroke, which are diagnostically complex and have a significant impact on patient quality of life and mortality.
• Investigation of neurological events, particularly stroke, must differentiate between inflammatory (vasculitis) and thrombotic causes, with thrombotic events being more common. Advanced imaging (e.g., vessel wall MRI) and cerebrospinal fluid analysis are crucial tools.
• Management requires a systematic diagnostic approach, considering lupus disease activity, antiphospholipid syndrome (APS), infections, metabolic disturbances, and medication effects, as treatments differ radically (e.g., immunosuppression vs. anticoagulation).

Summary

This transcription is from a medical podcast episode focusing on neuropsychiatric systemic lupus erythematosus (NPSLE). The discussion, led by a rheumatologist and a neurologist, begins by highlighting the broad and variable spectrum of NPSLE, which ranges from common mild symptoms like headache to severe syndromes such as stroke, acute confusional state, psychosis, and myelitis. The reported prevalence varies widely (4-91%), but recent criteria place it around 30-50%. A critical point emphasized is that only about one-third of neurological symptoms in lupus patients are directly attributable to lupus activity; the remaining two-thirds may stem from medication side effects, infections, metabolic issues, or other comorbidities. This makes accurate diagnosis essential to avoid inappropriate treatments like aggressive immunosuppression.

The conversation then details the severe central nervous system manifestations, focusing on three major challenges: acute confusional state/delirium, cognitive decline, and stroke. Acute confusional state is described as a sudden, severe syndrome with altered consciousness and content, requiring differentiation from pure psychosis and a thorough exclusion of other causes (infection, drugs, metabolic disturbance) before attributing it to lupus. Cognitive decline is often subtle and progressive, resembling a subcortical dementia pattern, and is difficult to assess and manage due to a lack of clear biomarkers linking treatment to outcomes.

A significant portion is dedicated to the diagnostic workup for stroke in lupus. The experts stress the need to distinguish between thrombotic events (more common, often associated with antiphospholipid syndrome) and inflammatory vasculitis (rarer). This differentiation guides treatment: immunosuppression for inflammation versus anticoagulation for thrombosis. Advanced neuroimaging, specifically vessel wall MRI (like "black blood" sequences), and cerebrospinal fluid analysis are highlighted as key tools to identify vessel wall inflammation suggestive of vasculitis. The discussion underscores that clinical context—such as disease duration, presence of traditional risk factors, and APS—is vital for interpretation.

Finally, the hosts outline a practical, systematic diagnostic framework for any neurological event in lupus, urging clinicians to consider five main etiologies: primary lupus activity, infection, metabolic disturbance, medication effect, or an unrelated disease. They conclude by reiterating the high morbidity, mortality, and profound impact on quality of life associated with NPSLE, underscoring the importance of a meticulous and nuanced approach to diagnosis and management.